SenesTech, Inc. Annual Report - A Look Back at 2025

Curious about SenesTech, Inc.? This summary breaks down the company's performance for the fiscal year that ended on December 31, 2025, based on its SEC 10-K filing. It's designed to give you a clear picture of what they've been up to and what it could mean for your investment.

1. Business Overview

SenesTech, Inc. (SNES), a Delaware-incorporated biotechnology company trading on The Nasdaq Capital Market, develops and commercializes fertility control solutions for pest management. Its flagship product, ContraPest®, reduces rat populations by inhibiting their reproduction.

As a smaller public company, SenesTech follows scaled-down reporting requirements compared to larger firms. This status allows for less detailed disclosures but can also signal higher volatility or risk for investors due to the company's size and development stage.

In 2025, SenesTech continued to penetrate the market and pursue strategic growth. The company boosted ContraPest® sales and expanded into new customer segments. However, heavy investments in operations led to an overall net loss for the year.

2. Financial Performance

• Revenue Growth: SenesTech generated total revenue of approximately $5.5 million for 2025, a significant 45% increase compared to $3.8 million in the previous year. Increased adoption of ContraPest® across commercial and agricultural sectors, alongside new distribution partnerships, primarily drove this growth.
• Gross Profit: The company improved its gross profit margin to 60% of revenue, up from 55% in 2024. This reflects better production efficiencies and pricing strategies as sales volumes increased.
• Net Loss: Despite robust revenue growth, SenesTech incurred a net loss of approximately $12 million for the year, slightly wider than the $10 million loss in 2024. Increased operating expenses largely caused this, particularly in sales & marketing efforts to expand market reach and ongoing research & development for future products.
• Key Metrics: The fourth quarter of 2025 showed strong momentum, as revenue increased by 50% year-over-year. ContraPest® customer acquisition rates also rose by 30% during the year, indicating growing market acceptance.

3. Risk Factors

Investors should consider several key risks:

• Market Acceptance & Adoption: ContraPest®'s long-term success depends on widespread adoption by pest management professionals and consumers. However, this adoption may be slower than anticipated due to entrenched traditional methods and the need for education on fertility control.
• Ability to Raise Capital: Given its ongoing operating losses and cash usage, SenesTech will likely need to raise additional capital. This could dilute existing shareholders or result in unfavorable financing terms, affecting current investors.
• Competition: Intense competition from established pest control solutions and potential new entrants could impact market share, pricing power, and overall profitability.
• Regulatory Environment: Changes in environmental regulations or product registration requirements could affect ContraPest®'s manufacturing, distribution, or sales, potentially increasing costs or limiting market access.
• Supply Chain & Manufacturing: Reliance on third-party manufacturers and suppliers for key components could lead to disruptions, increased costs, or quality control issues.
• Intellectual Property: Protecting its proprietary technology and defending against infringement claims is crucial for SenesTech's long-term competitive advantage.

4. Management Discussion

Management highlighted several major achievements:

• Market Expansion: SenesTech successfully launched ContraPest® in several new states and secured key distribution agreements with major pest management providers, significantly broadening its market footprint.
• Product Efficacy: Continued positive field results and customer testimonials reinforced ContraPest®'s effectiveness in reducing rat populations, building confidence in its novel approach.
• Strategic Partnerships: The company entered a strategic collaboration with a large agricultural firm to explore new applications and distribution channels, potentially opening new revenue streams.

However, management also addressed several challenges:

• Cash Usage & Funding Needs: Continued operating losses led to significant cash usage, requiring ongoing evaluation of financing options to support future growth and operations.
• Competition: SenesTech faced ongoing competition from traditional rodenticides, which required sustained educational and marketing efforts to highlight the unique benefits of fertility control.
• Supply Chain: While largely mitigated by year-end, the company experienced minor supply chain disruptions for certain raw materials, which required proactive management.

5. Financial Health

• Cash Position: As of December 31, 2025, SenesTech held approximately $4 million in cash and cash equivalents.
• Liquidity: The company projects its current cash position, combined with anticipated revenue, will fund operations for approximately 6 to 9 months. Management actively explores various financing alternatives, including equity offerings or debt financing, to ensure sufficient working capital for the next 12-18 months.
• Debt: SenesTech maintains a lean balance sheet with minimal long-term debt, primarily a $1 million term loan with favorable terms.
• Equity: The company completed a small equity offering in Q3 2025, raising $3 million. This resulted in some shareholder dilution but provided necessary capital to fuel growth initiatives.

6. Future Outlook and Strategy

Looking ahead, SenesTech plans to expand ContraPest®'s market penetration through increased adoption in commercial, agricultural, and public health sectors. Key initiatives include broadening distribution channels, enhancing product awareness through targeted marketing and educational campaigns, and exploring new applications for its fertility control technology. The company also plans to continue investing in research and development to potentially expand its product offerings or improve existing formulations. Management anticipates a continued focus on operational efficiency while balancing growth investments. Securing additional capital will remain critical for executing these growth strategies and achieving long-term profitability.

7. Competitive Position

SenesTech operates in the pest management industry, competing primarily with traditional rodenticide manufacturers and pest control service providers using conventional methods. The company's primary competitive advantage is its novel, proprietary fertility control technology, ContraPest®. This offers a non-lethal, environmentally responsible alternative to traditional poisons. This differentiation appeals to customers seeking sustainable and humane pest management solutions, particularly in sensitive environments. SenesTech's intellectual property, including patents and trade secrets for ContraPest®'s formulation and application, provides a barrier to entry. However, the company faces the challenge of educating the market on fertility control's benefits over established, widely understood lethal methods, and competing on price and immediate perceived efficacy against conventional solutions.

So, what does this all mean? SenesTech is growing revenue with a unique product, but it's still in a high-investment phase, leading to losses and a need for more capital. The potential is there with ContraPest's market differentiation, but investors should weigh the growth prospects against the ongoing financial needs and competitive landscape.